Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229851 · ClinicalTrials.gov registry record · Phase 3
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
NCT02229851 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 301 participants.
The verdict
NCT02229851, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
Study Summary
This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.
Interventions
- DRUG placebo
- DRUG somatropin
- DRUG somapacitan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2014-10-31 |
| Est. Completion | 2018-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02229851
The ClinicalTrials.gov registry entry for NCT02229851 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02229851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02229851 about?
NCT02229851 is a clinical study titled "Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.". This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.
What is the current status of trial NCT02229851?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2014-10-31. Estimated completion is 2018-05-07.
What interventions are being tested in trial NCT02229851?
The interventions under investigation include: placebo (DRUG), somatropin (DRUG), somapacitan (DRUG).
Who is sponsoring clinical trial NCT02229851?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.